Clinical trial · Interventional
Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery
Liver Cancer Institiute ,Fudan University
NCT01936233CI-TRIAL-00039868unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation the Treatment Outcome of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Drug | Aspirin | ALIAS |
| Lamivudine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Aspirin AND Lamivudine
- interventionNames
- Drug: Aspirin
- Drug: Lamivudine
- type
- ACTIVE_COMPARATOR
- label
- Lamivudine
- interventionNames
- Drug: Lamivudine
Primary outcomes (1)
- measure
- recurrence free survival
- timeFrame
- 36 months
Secondary outcomes (2)
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * Age ≥ 18 years and ≤ 75 years * At least one tumor nodule with one uni-dimension of ≥ 2 cm * Child-Pugh Class A or B * HBV-DNA\>10\^4 * Total bilirubin ≤ 1.5 x upper limit of normal * ALT and AST ≤ 2.0 x the upper limit of normal * PT-INR\<2.3,PTT \< 1.5 x upper limit of normal * Serum creatinine ≤ 1.5x upper limit of normal * Peripheral white blood cell count of or more than 3×10(9)/L * Peripheral platelet of or more than 50×10(9)/L * Expected survival time not less than 3 months * ECOG score 0-2 Exclusion Criteria: * Tumor thrombi in main branch of portal vein * Tumor involvement more than 70% of whole liver * With extrahepatic metastasis * Prior systemic chemotherapy or chemoembolization * Congestive heart failure \> NYHA class 2 * History of HIV infection * Active clinically serious infections (\> 2 NCI-CTC Version 3.0) * Recurrence of HCC after liver transplantation * Pregnant or breast-feeding * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * Known or suspected allergy to any agent given in association with this trial * Patients unable to swallow oral medication * Inclined to thrombosis * Inclined to hemorrhage or active hemorrhage with 1 month
References
Publications (0)
Data not yet available
No reference posted for this study.